MaxCyte (MXCT) Competitors

$1.10 +0.08 (+7.35%)

Closing price 03:59 PM Eastern

Extended Trading

$1.10 +0.01 (+0.46%)

As of 04:07 PM Eastern

MXCT vs. RMNI, RPAY, SY, SHAP, and ZH

Should you buy MaxCyte stock or one of its competitors? MarketBeat compares MaxCyte with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MaxCyte include Rimini Street (RMNI), Repay (RPAY), So-Young International (SY), Spree Acquisition Corp. 1 (SHAP), and Zhihu (ZH). These companies are all part of the "business services" industry.

How does MaxCyte compare to Rimini Street?

Rimini Street (NASDAQ:RMNI) and MaxCyte (NASDAQ:MXCT) are both small-cap business services companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

Rimini Street has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market. Comparatively, MaxCyte has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market.

In the previous week, Rimini Street had 11 more articles in the media than MaxCyte. MarketBeat recorded 16 mentions for Rimini Street and 5 mentions for MaxCyte. MaxCyte's average media sentiment score of 0.53 beat Rimini Street's score of 0.38 indicating that MaxCyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rimini Street	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MaxCyte	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

73.8% of Rimini Street shares are held by institutional investors. Comparatively, 68.8% of MaxCyte shares are held by institutional investors. 41.2% of Rimini Street shares are held by insiders. Comparatively, 4.1% of MaxCyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Rimini Street has a net margin of 8.30% compared to MaxCyte's net margin of -121.16%. MaxCyte's return on equity of -19.67% beat Rimini Street's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rimini Street	8.30%	-24.30%	1.64%
MaxCyte	-121.16%	-19.67%	-16.78%

Rimini Street presently has a consensus price target of $5.50, suggesting a potential upside of 57.37%. MaxCyte has a consensus price target of $5.50, suggesting a potential upside of 402.28%. Given MaxCyte's higher probable upside, analysts clearly believe MaxCyte is more favorable than Rimini Street.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rimini Street	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
MaxCyte	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Rimini Street has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Rimini Street, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rimini Street	$422.81M	0.77	$37.10M	$0.37	9.45
MaxCyte	$33.03M	3.55	-$44.63M	-$0.43	N/A

Summary

Rimini Street beats MaxCyte on 9 of the 14 factors compared between the two stocks.

How does MaxCyte compare to Repay?

Repay (NASDAQ:RPAY) and MaxCyte (NASDAQ:MXCT) are both small-cap business services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

In the previous week, Repay had 4 more articles in the media than MaxCyte. MarketBeat recorded 9 mentions for Repay and 5 mentions for MaxCyte. Repay's average media sentiment score of 0.87 beat MaxCyte's score of 0.53 indicating that Repay is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Repay	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MaxCyte	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

MaxCyte has lower revenue, but higher earnings than Repay. MaxCyte is trading at a lower price-to-earnings ratio than Repay, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repay	$312.73M	1.02	-$256.72M	-$3.06	N/A
MaxCyte	$33.03M	3.55	-$44.63M	-$0.43	N/A

Repay has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market. Comparatively, MaxCyte has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market.

Repay has a net margin of -82.73% compared to MaxCyte's net margin of -121.16%. Repay's return on equity of 10.45% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repay	-82.73%	10.45%	4.56%
MaxCyte	-121.16%	-19.67%	-16.78%

Repay currently has a consensus target price of $5.41, suggesting a potential upside of 60.66%. MaxCyte has a consensus target price of $5.50, suggesting a potential upside of 402.28%. Given MaxCyte's higher possible upside, analysts plainly believe MaxCyte is more favorable than Repay.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repay	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22
MaxCyte	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

82.7% of Repay shares are held by institutional investors. Comparatively, 68.8% of MaxCyte shares are held by institutional investors. 12.0% of Repay shares are held by insiders. Comparatively, 4.1% of MaxCyte shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Repay beats MaxCyte on 12 of the 16 factors compared between the two stocks.

How does MaxCyte compare to So-Young International?

MaxCyte (NASDAQ:MXCT) and So-Young International (NASDAQ:SY) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

In the previous week, MaxCyte had 3 more articles in the media than So-Young International. MarketBeat recorded 5 mentions for MaxCyte and 2 mentions for So-Young International. So-Young International's average media sentiment score of 0.63 beat MaxCyte's score of 0.53 indicating that So-Young International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MaxCyte	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
So-Young International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

So-Young International has higher revenue and earnings than MaxCyte. So-Young International is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$33.03M	3.55	-$44.63M	-$0.43	N/A
So-Young International	$1.52B	0.19	-$34.65M	-$0.33	N/A

MaxCyte has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market. Comparatively, So-Young International has a beta of 2.1, indicating that its stock price is 110% more volatile than the broader market.

So-Young International has a net margin of -15.97% compared to MaxCyte's net margin of -121.16%. So-Young International's return on equity of -12.54% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-121.16%	-19.67%	-16.78%
So-Young International	-15.97%	-12.54%	-8.55%

MaxCyte currently has a consensus target price of $5.50, suggesting a potential upside of 402.28%. So-Young International has a consensus target price of $5.50, suggesting a potential upside of 92.64%. Given MaxCyte's stronger consensus rating and higher probable upside, equities research analysts clearly believe MaxCyte is more favorable than So-Young International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
So-Young International	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

68.8% of MaxCyte shares are owned by institutional investors. Comparatively, 35.3% of So-Young International shares are owned by institutional investors. 4.1% of MaxCyte shares are owned by company insiders. Comparatively, 16.7% of So-Young International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

So-Young International beats MaxCyte on 9 of the 16 factors compared between the two stocks.

How does MaxCyte compare to Spree Acquisition Corp. 1?

MaxCyte (NASDAQ:MXCT) and Spree Acquisition Corp. 1 (NYSE:SHAP) are both small-cap business services companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

68.8% of MaxCyte shares are owned by institutional investors. Comparatively, 9.9% of Spree Acquisition Corp. 1 shares are owned by institutional investors. 4.1% of MaxCyte shares are owned by company insiders. Comparatively, 58.4% of Spree Acquisition Corp. 1 shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, MaxCyte had 5 more articles in the media than Spree Acquisition Corp. 1. MarketBeat recorded 5 mentions for MaxCyte and 0 mentions for Spree Acquisition Corp. 1. MaxCyte's average media sentiment score of 0.53 beat Spree Acquisition Corp. 1's score of 0.00 indicating that MaxCyte is being referred to more favorably in the media.

Company	Overall Sentiment
MaxCyte	Positive
Spree Acquisition Corp. 1	Neutral

MaxCyte has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market. Comparatively, Spree Acquisition Corp. 1 has a beta of -0.02, indicating that its share price is 102% less volatile than the broader market.

Spree Acquisition Corp. 1 has lower revenue, but higher earnings than MaxCyte. Spree Acquisition Corp. 1 is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$33.03M	3.55	-$44.63M	-$0.43	N/A
Spree Acquisition Corp. 1	N/A	N/A	$4.35M	-$0.01	N/A

Spree Acquisition Corp. 1 has a net margin of 0.00% compared to MaxCyte's net margin of -121.16%. MaxCyte's return on equity of -19.67% beat Spree Acquisition Corp. 1's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-121.16%	-19.67%	-16.78%
Spree Acquisition Corp. 1	N/A	-22.17%	6.72%

MaxCyte presently has a consensus target price of $5.50, suggesting a potential upside of 402.28%. Given MaxCyte's stronger consensus rating and higher probable upside, research analysts plainly believe MaxCyte is more favorable than Spree Acquisition Corp. 1.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Spree Acquisition Corp. 1	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

MaxCyte beats Spree Acquisition Corp. 1 on 10 of the 15 factors compared between the two stocks.

How does MaxCyte compare to Zhihu?

MaxCyte (NASDAQ:MXCT) and Zhihu (NYSE:ZH) are both small-cap business services companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

68.8% of MaxCyte shares are owned by institutional investors. Comparatively, 28.9% of Zhihu shares are owned by institutional investors. 4.1% of MaxCyte shares are owned by company insiders. Comparatively, 13.6% of Zhihu shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, MaxCyte had 4 more articles in the media than Zhihu. MarketBeat recorded 5 mentions for MaxCyte and 1 mentions for Zhihu. MaxCyte's average media sentiment score of 0.53 beat Zhihu's score of 0.00 indicating that MaxCyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MaxCyte	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Zhihu	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MaxCyte has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market. Comparatively, Zhihu has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Zhihu has higher revenue and earnings than MaxCyte. Zhihu is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$33.03M	3.55	-$44.63M	-$0.43	N/A
Zhihu	$393.10M	0.73	-$27.58M	-$0.36	N/A

Zhihu has a net margin of -7.18% compared to MaxCyte's net margin of -121.16%. Zhihu's return on equity of -4.82% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-121.16%	-19.67%	-16.78%
Zhihu	-7.18%	-4.82%	-3.57%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Zhihu	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

MaxCyte beats Zhihu on 9 of the 16 factors compared between the two stocks.

Get MaxCyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MXCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MXCT vs. The Competition

Export

Metric	MaxCyte	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$117.30M	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-2.96	18.81	20.87	25.61
Price / Sales	3.55	181.76	521.62	63.45
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	0.68	6.75	9.86	6.71
Net Income	-$44.63M	$24.11M	$3.55B	$333.77M
7 Day Performance	25.65%	0.11%	-0.26%	0.40%
1 Month Performance	24.23%	0.87%	1.39%	4.03%
1 Year Performance	-50.23%	78.18%	41.07%	36.33%

MaxCyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MXCT MaxCyte	2.7742 of 5 stars	$1.10 +7.4%	$5.50 +402.3%	-53.6%	$117.30M	$33.03M	N/A	80	News Coverage Earnings Report
RMNI Rimini Street	4.5236 of 5 stars	$3.89 flat	$5.50 +41.4%	-0.8%	$356.57M	$422.81M	10.51	1,980
RPAY Repay	4.1857 of 5 stars	$3.57 -10.8%	$5.33 +49.4%	-16.2%	$325.47M	$309.26M	N/A	580	Analyst Revision
SY So-Young International	2.401 of 5 stars	$3.16 +5.3%	$5.50 +74.1%	-77.3%	$320.53M	$1.52B	N/A	1,800	News Coverage
SHAP Spree Acquisition Corp. 1	N/A	$10.91 flat	N/A	N/A	$283.07M	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MXCT) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MaxCyte (MXCT) Competitors

MXCT vs. RMNI, RPAY, SY, SHAP, and ZH

How does MaxCyte compare to Rimini Street?

Summary

How does MaxCyte compare to Repay?

Summary

How does MaxCyte compare to So-Young International?

Summary

How does MaxCyte compare to Spree Acquisition Corp. 1?

Summary

How does MaxCyte compare to Zhihu?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MXCT vs. The Competition

MaxCyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MaxCyte (MXCT) Competitors

MXCT vs. RMNI, RPAY, SY, SHAP, and ZH

How does MaxCyte compare to Rimini Street?

Which has more risk and volatility, RMNI or MXCT?

Does the media prefer RMNI or MXCT?

Do institutionals and insiders have more ownership in RMNI or MXCT?

Is RMNI or MXCT more profitable?

Do analysts recommend RMNI or MXCT?

Which has higher earnings and valuation, RMNI or MXCT?

Summary

How does MaxCyte compare to Repay?

Does the media prefer RPAY or MXCT?

Which has stronger valuation & earnings, RPAY or MXCT?

Which has more risk & volatility, RPAY or MXCT?

Is RPAY or MXCT more profitable?

Do analysts recommend RPAY or MXCT?

Do insiders & institutionals have more ownership in RPAY or MXCT?

Summary

How does MaxCyte compare to So-Young International?

Does the media favor MXCT or SY?

Which has preferable valuation & earnings, MXCT or SY?

Which has more volatility & risk, MXCT or SY?

Is MXCT or SY more profitable?

Do analysts rate MXCT or SY?

Do institutionals & insiders hold more shares of MXCT or SY?

Summary

How does MaxCyte compare to Spree Acquisition Corp. 1?

Do insiders and institutionals hold more shares of MXCT or SHAP?

Does the media refer more to MXCT or SHAP?

Which has more risk & volatility, MXCT or SHAP?

Which has better earnings & valuation, MXCT or SHAP?

Is MXCT or SHAP more profitable?

Do analysts rate MXCT or SHAP?

Summary

How does MaxCyte compare to Zhihu?

Do insiders and institutionals hold more shares of MXCT or ZH?

Does the media refer more to MXCT or ZH?

Which has more risk & volatility, MXCT or ZH?

Which has better earnings & valuation, MXCT or ZH?

Is MXCT or ZH more profitable?

Do analysts rate MXCT or ZH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MXCT vs. The Competition

MaxCyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools